Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea FDA Moves To Elevate Patent-Approval Team To A Division

This article was originally published in PharmAsia News

Executive Summary

As it implements provisions in the U.S.-South Korea FTA, KFDA is creating a division to oversee patent-approval issues, upgrading the status and manpower of a temporary task force team.

You may also be interested in...

Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers

SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products

Pharma, Medical Device Provisions Outlined In Korea, EU Free Trade Agreement

SEOUL - South Korea's Ministry of Foreign Affairs and Trade unveiled the content of pharmaceutical and medical device provisions in its Free Trade Agreement with the EU, which was initialed by its Trade Minister Kim Jong-hoon and EU Trade Commissioner Catherine Ashton in Brussels Oct. 15

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts